Feature Regenicin readying clinical trials of NovaDerm skin substitute By Len Zehr Regenicin (OTC:RGIN) is completing validation of its NovaDerm skin substitute at a leading institute of technology in the U.S and plans to seek FDA approval to move into clinical trials in the second half of... June 30, 2015